Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy (NCT04691817)

🧪 Interventions in This Study

• Atezolizumab (DRUG)
• Tocilizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania

📞 Contact the Study Coordinator

Phone: (215) 220-9703

Email: melissa.volpe@pennmedicine.upenn.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lung Cancer, Nonsmall Cell

• Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients — Charlotte, North Carolina
• Palliative Thoracic ImmunoRT — Toronto, Ontario

Explore by condition: All Lung Cancer, Nonsmall Cell clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.